Literature DB >> 18231756

Establishment of lymphangioma model and a study on the promoting effect of murine melanoma cell B16-F1 on the lymphangiogenesis in vitro.

Siyuan Chen1, Aijun Chen, Changzheng Huang.   

Abstract

To establish an animal model of benign lymphangiomas of C57BL/6 mouse in vitro and to observe the effect of mouse ascites melanoma cell B16-F1 on the lymphangiogenesis, 16 C57BL/6 mice aged 8 weeks were given two intraperitoneal injections of incomplete Freund's adjuvant at a 15-day interval. The induced neoplasms were studied histopathologically and the neoplasms specimens were immunohistochemically examined for the expressions of VEGF-C (vascular endothelial growth factor-C) and Flt-4 (VEGFR-3, vascular endothelial growth factor receptor-3). The neoplasms were harvested and embedded in fibrin gel for culture in conditioned medium of B16-F1 cells in vitro and observed under inverted microscope. Our results showed that white solid tumor masses developed in peritoneal cavity after the induction. The tumors were confirmed to be lymphangioma by gross and histological examination. The tumor cells expressed both VEGF-C and Flt-4. Lymphatic capillaries coming from lymphangioma specimen grew into the gel and the conditioned medium of B16-F1 cells was found to be able to promote the growth of the vessels. It is concluded that intraperitoneal injection of incomplete Freund's adjuvant is a good method for inducing benign lymphangiomas in mouse and B16-F1 cells can promote lymphangiogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18231756     DOI: 10.1007/s11596-007-0630-z

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  11 in total

Review 1.  Lymphatic dissemination of tumour cells and the formation of micrometastases.

Authors:  Philippe O Van Trappen; Michael S Pepper
Journal:  Lancet Oncol       Date:  2002-01       Impact factor: 41.316

Review 2.  Embryonic lymphangiogenesis.

Authors:  J Wilting; H Neeff; B Christ
Journal:  Cell Tissue Res       Date:  1999-07       Impact factor: 5.249

Review 3.  Lymphatic versus blood vascular endothelial growth factors and receptors in humans.

Authors:  T A Partanen; K Paavonen
Journal:  Microsc Res Tech       Date:  2001-10-15       Impact factor: 2.769

4.  A comprehensive prognostic index to predict survival based on multiple comorbidities: a focus on breast cancer.

Authors:  S T Fleming; A Rastogi; A Dmitrienko; K D Johnson
Journal:  Med Care       Date:  1999-06       Impact factor: 2.983

Review 5.  Lymphangiogenesis and tumor metastasis: myth or reality?

Authors:  M S Pepper
Journal:  Clin Cancer Res       Date:  2001-03       Impact factor: 12.531

6.  Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis.

Authors:  M Skobe; T Hawighorst; D G Jackson; R Prevo; L Janes; P Velasco; L Riccardi; K Alitalo; K Claffey; M Detmar
Journal:  Nat Med       Date:  2001-02       Impact factor: 53.440

Review 7.  Pathological significance of vascular endothelial growth factor A isoform expression in human cancer.

Authors:  Masato Nakamura; Yoshiyuki Abe; Tetsuji Tokunaga
Journal:  Pathol Int       Date:  2002 May-Jun       Impact factor: 2.534

8.  Prognosis of breast-carcinoma lymphagenesis evaluated by immunohistochemical investigation of vascular-endothelial-growth-factor receptor 3.

Authors:  J Jacquemier; M P Mathoulin-Portier; R Valtola; E Charafe-Jauffret; J Geneix; G Houvenaeghel; B Puig; V J Bardou; J Hassoun; P Viens; D Birnbaum
Journal:  Int J Cancer       Date:  2000-01-20       Impact factor: 7.396

9.  Vascular endothelial growth factor splice variants and their prognostic value in breast and ovarian cancer.

Authors:  Margit Stimpfl; Dan Tong; Barbara Fasching; Eva Schuster; Andreas Obermair; Sepp Leodolter; Robert Zeillinger
Journal:  Clin Cancer Res       Date:  2002-07       Impact factor: 12.531

Review 10.  Vascular growth factors and lymphangiogenesis.

Authors:  Lotta Jussila; Kari Alitalo
Journal:  Physiol Rev       Date:  2002-07       Impact factor: 37.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.